The molecular determinants of tumor cell sensitivity and resistance to antibody-dependent cellular cytotoxicity (ADCC)

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Georgetown University-Graduate School of Arts & Sciences

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Perforin forms transient pores on the target cell plasma membrane to facilitate rapid access of granzymes during killer cell attack.

  2013cited by this paper
• Cetuximab-mediated tumor regression depends on innate and adaptive immune responses.

  2013cited by this paper
• Rapid activation receptor- or IL-2-induced lytic granule convergence in human natural killer cells requires Src, but not downstream signaling.

  2013cited by this paper
• Oncogenic RAS simultaneously protects against anti-EGFR antibody-dependent cellular cytotoxicity and EGFR signaling blockade

  2013cited by this paper
• A phase I study of the BCR-ABL tyrosine kinase inhibitor nilotinib and cetuximab in patients with solid tumors that can be treated with cetuximab.

  2013cited by this paper
• Identification of SERPINB1 As a Physiological Inhibitor of Human Granzyme H

  2013cited by this paper
• NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17).

  2013cited by this paper
• Shedding of soluble epidermal growth factor receptor (sEGFR) is mediated by a metalloprotease/fibronectin/integrin axis and inhibited by cetuximab.

  2013cited by this paper
• Rituximab causes a polarization of B cells that augments its therapeutic function in NK-cell-mediated antibody-dependent cellular cytotoxicity.

  2013cited by this paper
• Imaging burst kinetics and spatial coordination during serial killing by single natural killer cells

  2013cited by this paper
• Exhaustion of Cytotoxic Effector Systems May Limit Monoclonal Antibody-Based Immunotherapy in Cancer Patients

  2012cited by this paper
• Natural killer cell‐produced IFN‐γ and TNF‐α induce target cell cytolysis through up‐regulation of ICAM‐1

  2012cited by this paper
• Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.

  2012cited by this paper
• A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine.

  2012cited by this paper
• Epithelial and Mesenchymal Cell Biology ROCK Inhibitor and Feeder Cells Induce the Conditional Reprogramming of Epithelial Cells

  2012cited by this paper
• NIH Image to ImageJ: 25 years of image analysis

  2012cited by this paper
• Intra-tumour heterogeneity: a looking glass for cancer?

  2012influential reference
• Enhancement of natural killer cell effector functions against selected lymphoma and leukemia cell lines by dasatinib

  2012cited by this paper
• Trastuzumab emtansine for HER2-positive advanced breast cancer.

  2012cited by this paper
• The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers

  2012cited by this paper
• Impact of Epidermal Growth Factor Receptor (EGFR) Cell Surface Expression Levels on Effector Mechanisms of EGFR Antibodies

  2012influential reference
• Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

  2012cited by this paper
• Brentuximab vedotin

  2012cited by this paper
• Sphingosine Kinase 1 Overexpression Contributes to Cetuximab Resistance in Human Colorectal Cancer Models

  2012cited by this paper
• The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data.

  2012influential reference
• Oncogenic KRAS impairs EGFR antibodies' efficiency by C/EBPβ-dependent suppression of EGFR expression.

  2012cited by this paper
• Conditionally reprogrammed cells represent a stem-like state of adult epithelial cells

  2012cited by this paper
• Inhibition of TGF-β Enhances the In Vivo Antitumor Efficacy of EGF Receptor–Targeted Therapy

  2012cited by this paper
• Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond

  2012influential reference
• NK cell MHC class I specific receptors (KIR): from biology to clinical intervention.

  2012cited by this paper
• Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines

  2012cited by this paper
• Cetuximab in combination with anti-human IgG antibodies efficiently down-regulates the EGF receptor by macropinocytosis.

  2012cited by this paper
• Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer

  2012cited by this paper
• Direct and immune mediated antibody targeting of ERBB receptors in a colorectal cancer cell-line panel

  2012cited by this paper
• Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer

  2012influential reference
• The ERBB network: at last, cancer therapy meets systems biology

  2012cited by this paper
• Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma

  2012cited by this paper
• Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.

  2011cited by this paper
• Differential requirements for CD45 in NK-cell function reveal distinct roles for Syk-family kinases.

  2011cited by this paper
• Influence of affinity and antigen internalization on the uptake and penetration of Anti-HER2 antibodies in solid tumors.

  2011cited by this paper
• Activating and inhibitory receptors of natural killer cells

  2011cited by this paper
• Microenvironment and Immunology Antibody-Dependent Cell Cytotoxicity Synapses Form in Mice during Tumor-Specific Antibody Immunotherapy

  2011cited by this paper
• Rituximab infusion induces NK activation in lymphoma patients with the high-affinity CD16 polymorphism.

  2011cited by this paper
• Molecular signatures database (MSigDB) 3.0

  2011cited by this paper
• The Split-Apply-Combine Strategy for Data Analysis

  2011cited by this paper
• Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion

  2011influential reference
• Engineering Upper Hinge Improves Stability and Effector Function of a Human IgG1

  2011cited by this paper
• Multiple distinct NK-cell synapses.

  2011cited by this paper
• The molecular biology of head and neck cancer

  2011cited by this paper
• Epidermal Growth Factor Receptor (EGFR) Antibody-Induced Antibody-Dependent Cellular Cytotoxicity Plays a Prominent Role in Inhibiting Tumorigenesis, Even of Tumor Cells Insensitive to EGFR Signaling Inhibition

  2011cited by this paper
• The Two Faces of Interferon-γ in Cancer

  2011cited by this paper
• Advances in the assessment and control of the effector functions of therapeutic antibodies

  2011cited by this paper
• Antibody-Radionuclide Conjugates for Cancer Therapy: Historical Considerations and New Trends

  2011cited by this paper
• 2B4 Engagement Mediates Rapid LFA-1 and Actin-Dependent NK Cell Adhesion to Tumor Cells as Measured by Single Cell Force Spectroscopy

  2011cited by this paper
• Cytoskeletal stabilization of inhibitory interactions in immunologic synapses of mature human dendritic cells with natural killer cells.

  2011cited by this paper
• Development trends for human monoclonal antibody therapeutics

  2010cited by this paper
• R Development Core Team (2010): R: A language and environment for statistical computing

  2010cited by this paper
• Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer

  2010cited by this paper
• Tethering of Intercellular Adhesion Molecule on Target Cells Is Required for LFA-1–Dependent NK Cell Adhesion and Granule Polarization

  2010cited by this paper
• Monoclonal antibodies: versatile platforms for cancer immunotherapy

  2010cited by this paper
• U.S. Food and Drug Administration Approval: Ofatumumab for the Treatment of Patients with Chronic Lymphocytic Leukemia Refractory to Fludarabine and Alemtuzumab

  2010cited by this paper
• CD57 defines a functionally distinct population of mature NK cells in the human CD56dimCD16+ NK-cell subset.

  2010cited by this paper
• Understanding resistance to EGFR inhibitors—impact on future treatment strategies

  2010cited by this paper
• In vivo cytotoxicity of type I CD20 antibodies critically depends on Fc receptor ITAM signaling.

  2010cited by this paper
• ABL Tyrosine Kinases: Evolution of Function, Regulation, and Specificity

  2010cited by this paper
• Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy.

  2010cited by this paper
• The BCR/ABL‐inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity

  2010cited by this paper
• Synthetic Lethal Screen of an EGFR-Centered Network to Improve Targeted Therapies

  2010influential reference
• Affinity and Avidity in Antibody-Based Tumor Targeting

  2009cited by this paper
• Minimal requirement for induction of natural cytotoxicity and intersection of activation signals by inhibitory receptors.

  2009cited by this paper
• Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a "vaccinal effect" of rituximab.

  2009cited by this paper
• Natural killer cell IFN-gamma levels predict long-term survival with imatinib mesylate therapy in gastrointestinal stromal tumor-bearing patients.

  2009cited by this paper
• Genetic prognostic and predictive markers in colorectal cancer

  2009cited by this paper
• Cetuximab-mediated antibody-dependent cellular cytotoxicity (ADCC) against tumor cell lines characterized for EGFR expression and K-ras mutation.

  2009cited by this paper
• Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells

  2009influential reference
• Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan.

  2009influential reference
• AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance.

  2009cited by this paper
• Integrin-dependent organization and bidirectional vesicular traffic at cytotoxic immune synapses.

  2009cited by this paper
• Immunoselection of breast and ovarian cancer cells with trastuzumab and natural killer cells: selective escape of CD44high/CD24low/HER2low breast cancer stem cells.

  2009influential reference
• FcγRIIIa polymorphisms and cetuximab induced cytotoxicity in squamous cell carcinoma of the head and neck

  2009cited by this paper
• Simultaneous Inference in General Parametric Models

  2008cited by this paper
• Depletion of the C3 component of complement enhances the ability of rituximab-coated target cells to activate human NK cells and improves the efficacy of monoclonal antibody therapy in an in vivo model.

  2008cited by this paper
• Up on the tightrope: natural killer cell activation and inhibition

  2008influential reference
• A Polymorphism in the Complement Component C1qA Correlates with Prolonged Response Following Rituximab Therapy of Follicular Lymphoma

  2008cited by this paper
• The c-Abl tyrosine kinase regulates actin remodeling at the immune synapse.

  2008cited by this paper
• Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer.

  2008cited by this paper
• Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells.

  2008cited by this paper
• Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members

  2008cited by this paper
• lumi: a pipeline for processing Illumina microarray

  2008cited by this paper
• CD16+ gammadelta T cells mediate antibody dependent cellular cytotoxicity: potential mechanism in the pathogenesis of multiple sclerosis.

  2008influential reference
• Blocking NK Cell Inhibitory Self-Recognition Promotes Antibody-Dependent Cellular Cytotoxicity in a Model of Anti-Lymphoma Therapy1

  2008influential reference
• Fcgamma receptors as regulators of immune responses.

  2008cited by this paper
• Lattice: Multivariate Data Visualization with R

  2008cited by this paper
• Functions of natural killer cells

  2008cited by this paper
• Formation and function of the lytic NK-cell immunological synapse

  2008cited by this paper
• Dasatinib suppresses in vitro natural killer cell cytotoxicity.

  2008cited by this paper
• Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.

  2008cited by this paper
• Fc-receptors as regulators of immunity.

  2007cited by this paper
• Direct repression of cyclin D1 by SIP1 attenuates cell cycle progression in cells undergoing an epithelial mesenchymal transition.

  2007cited by this paper
• Reshaping Data with the reshape Package

  2007cited by this paper

• NK92 cells and peripheral blood NK cells respond oppositely upon dasatinib treatment

  2024cites this paper
• A molecular perspective on rituximab: A monoclonal antibody for B cell non Hodgkin lymphoma and other affections.

  2016cites this paper